posted
Great day all!! remember...patience is most important when playing high quality penny stocks,they really do pay off in the end! I was very pleased selling BIPH over $2 when I bought it at .09 thru .20! I hope to do the same here!
have a great night all,getting ready for Halloween!
posted
I was just re-reading the last PR and the more I look into this company the more I like it,take some time and really read this press release,it gives you a good idea where they will be heading!
CalbaTech Featured in Drug Discovery News Article
IRVINE, Calif., Oct. 12 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, recently was featured in Drug Discovery News (http://www.drugdiscoverynews.com), which is a newspaper on the Internet for the pharmaceutical industry. The story follows in full:
In announcing plans by its Columbia, Md.-based subsidiary K-D Medical to acquire a new facility with two validated, class 100 clean rooms, CalbaTech not only had expanded manufacture of products on its mind, but also the opportunity to profit by leasing part of the new space to other companies -- some of whom could be engaged in drug discovery efforts.
Previously, K-D Medical's facilities consisted solely of a 7,000 square foot operation located between Baltimore and Washington, D.C., near the National Institutes of Health (NIH)-- for which K-D Medical is a "primary vendor," according to CalbaTech. That facility, like the new one, has two clean rooms for sterile production, as well as a room for contract medical packaging, a warehouse and a walk-in cold box.
Of direct and primary interest to K-D Medical and its parent company, CalbaTech, is that the additional space will provide for expanding the current custom product offerings and better serving the needs of both existing and new customers, including drug discovery companies, drug production operations, universities, government agencies and others in the pharmaceutical market.
K-D Medical's founder, John Powers, adds that the new clean rooms -- along with a complete quality control laboratory at the new facility -- will also allow the company to manufacture higher quality products.
"This is a very good position for us, as we increase sales to the National Institutes of Health, major universities and pharmaceutical companies," Powers says.
In addition to expanding its manufacturing and client service capabilities, K-D Medical is also looking forward to leasing opportunities. One of the new clean rooms will be used solely by K-D, while the other one will be usable by contract customers.
"These new facilities allow K-D Medical to open new manufacturing and clean room leasing opportunities with pharmaceutical and other companies, opportunities that did not exist prior to this," says James DeOlden, chairman and chief executive officer of CalbaTech. "We are very bullish on our subsidiary's future."
"There are two types of potential customers for K-D through the new facility," Powers reports. "First, the incubator company who needs clean room operation capability and second, the large pharmaceutical company who may want to run prototype or small batch productions for research use only."
K-D will offer the opportunity for companies to utilize the approximately 1,000 square feet of available class 100 clean room, along with the adjacent 4,000 square feet of fully furnished and fitted laboratory space, Powers says, adding that the facility is ISO 9002 certified and FDA compliant.
"K-D is of the belief that a need exists for various companies who cannot afford the capital expense of approximately $100,000 to establish this type of high-end clean room and laboratory," Powers explains, "or who believe that such space rental at the K-D facility would allow them to maximize their existing production facilities, and to do so in our facility on a daily, monthly or annual basis."
CalbaTech provides products and platforms to the biotech and pharmaceutical research market and to academic institutions, while K-D Medical is focused on manufacturing bacterial and yeast growth media, microbiological biological buffers and reagents. As of the filing of its 10KSB documentation in May, K-D Medical's production was more than a half million liters of molecular biology reagents and buffers and nearly three quarters of a million bacterial and yeast biological media products yearly -- which were sold to "every major pharmaceutical company" in the United States, according to CalbaTech.
The announcement of the new facility acquisition was followed a day later by CalbaTech's announcement that its overall corporate revenues for the six months ended June 30 totaled $625,345, up from $58,217 for the same period in 2004.
That announcement also had good things to say about K-D Medical, particularly in relation to another CalbaTech subsidiary, Molecula, which provides antisense oligonucleotides to researchers worldwide.
"We are confident that Molecula and K-D Medical will continue to complement each other and that our cross-marketing plans will allow these two subsidiaries to generate $1.5 million in revenues in the current fiscal year," DeOlden noted in the revenue announcement.
About CalbaTech
CalbaTech, Inc. (OTC Bulletin Board: CLBE) is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions.
About K-D Medical, Inc.
K-D Medical, located in the heart of the Maryland Biotech Corridor, is one of the nation's leading manufacturers of microbiological culture media and other research reagents. K-D Medical's products are used in drug discovery, microbiology labs and biopharmaceutical production. The company is headquartered in Columbia, Maryland.
posted
QUESTION BY A POSTER--I read in a new article recently that the current value of the stem cell industry in the year 2005 is about 500 million dollars. They estimate that the industry by the year 2010 only five years from now will be worth 30 Billion dollars a year...
1) With a 60 times the revenue in 2010..how will this affect the value of stem cell stocks...
Does this mean the Stocks in Stem cells will be worth more...
How will this affect the stock
ANSWER--Absolutely it would effect probably all good stem cell related companies especially those that are focused on adult stem cells because by the embryonic stem cells will be no more.Between stem cell extraction and banking many good penny stem cell stocks like CLBE will increase PPS multiple times and I feel quite confident saying that!As for you numbers I believe they are quite accurate and will find supporting info,I to read how they expect that increase and its massive!
that link takes you to many other infomative press releases and various info,the adult stem cell industry is going to be measure in the hundreds of billions without any doubt in my mind.CLBE is linked up with just about all of the major pharm companies and when you read some of the links you will see why that is so important. These companies are throwing around tens of millions of dollars into stem cell related companies,trust me,they know exactly what they are doing.Heres just a few examples THIS WEEK
U of MN researchers awarded more than $20 million for stem cell and natural killer cell research 31 Oct 2005 17:36 GMT ... researchers awarded more than $20 million for stem cell and natural killer cell research University of ... over five years to conduct research on stem cells and natural killer cells for treatment of ...
CA Stem Cell Institute Must Allow Taxpayers, Patients to Have a Controlling Interest in New Medical Breakthroughs; Consumer Group Calls on Regulators to Protect $3 Billion Investment 31 Oct 2005 17:35 GMT ... CA Stem Cell Institute Must Allow Taxpayers, Patients to Have ... with the use of adult cord blood stem cells. Prop 71 stem cell research grants could ...
A*Star to invest S$70m over 3 years to boost stem cell research 31 Oct 2005 15:35 GMT ... : A*Star's Biomedical Research Council has earmarked S$70 million over three years to support stem cell research collaborations. The move is one of four proposals aimed at bringing scientific research ...
Soaring Biomedical Research Funding a Boon to Innovators and Investors; Investment Grows 154% to Estimated $94 Billion in Last Decade, Strengthening R&D Pipeline for Emerging Growth Biotech Companies 31 Oct 2005 14:35 GMT ... company's scientific collaborators at Tel Aviv University had successfully implanted human bone marrow derived stem cells into animal models of Parkinson's disease and observed improved motor function within just two ...
Dr. Reddy's Reports Q2 FY06 Revenue of Rs. 5,803 million; YoY Growth of 7%; Net Income Increases by 72% to Rs. 890 Million 31 Oct 2005 14:35 GMT ...
posted
bringing some info up front for any newbies.
CalbaTech (CLBE) is definitely a great mid to long term investment imo.(3 to 12 months or more)
reading the most recent 10K, thought I'd share some of my favorite quotes:
1. "The company believes that it will report a net profit for 2005."
2. Regarding LifeStem's stem cell banking service: "It is not unreasonable to project potential revenues approaching $100 Million within 36 to 48 months with as few as 10,000 clients."
3. Officers and Directors:
James DeOlden, Esq. -- CEO: B.A. from UVA, J.D. from Whittier Law School, he has a securities law practice.
Edward Deese -- President, COO: B.S. in Economics from University of California, Irvine.
John Gordon, Ph.D. -- CTO: B.Sc. Honors in Cell Biology, Ph.D. from University of Glasgow.
4. Scientific Advisory Board:
Kary B. Mullis: Recieved the 1993 Nobel Prize in chemistry for his invention of the polymerase chain reaction (PCR). Ph.D. from Berkeley, B.S. from Georgia Institute of Technology.
Basically, the company looks like it's going to be profitable soon and the directors and advisors appear to be very intelligent people who are leaders in their respective fields.
in a new article recently that the current value of the stem cell industry in the year 2005 is about 500 million dollars. They estimate that the industry by the year 2010 only five years from now will be worth 30 Billion dollars a year...
Catholic Church Funds Adult Stem Cell Research
The Catholic Church in Korea has decided to donate money for adult stem cell research. The move comes amid strong Vatican opposition to embryonic stem cell research and is reflects support for research into an alternative. The Church has been among the most vocal opponents of embryonic stem cell research based on the belief that embryos are human beings. In Korea, a country leading that field of science, the Catholic Church is donating millions of dollars to aid research involving adult stem cells in the hope of reducing the increasing reliance on embryonic stem cells to treat hard-to-cure diseases.
"The research harms the integrity of life, and that's why we cannot accept the use of embryos," the church said. It wants to fund research on adult stem cells derived from bone marrow or umbilical cords that would otherwise be discarded after a baby is born. They say this is more practical and does not cause ethical controversy.
CalbaTech now looks to build a portfolio by buying companies that develop new technologies to sell or license; it also targets universities that are planning to license technology developed in academic labs. The firm is interested in products that will generate sales or licensing revenue within two years and need less than $1 million. Among its acquisitions are MolecularWare and iStem Technologies
Pro-Life Congressman and Dr. J Seek Adult Stem Cell Research Bill
Washington, DC (LifeNews.com) -- A leading pro-life congressman and former Philadelphia 76ers basketball star Julius "Dr. J" Erving teamed up at a press conference Thursday to ask the Senate to pass a House-approved bill that would promote adult stem cell research using umbilical cord blood. The bill provides funding to use stem cells from umbilical cord blood, which have proven to be the most effective and the House approved HR 2520 434-1 in May.
interesting info posted by Umpolung on another board...
Kary Mullis is an "interesting" read:
"Sometimes a good idea comes to you when you are not looking for it. Through an improbable combination of coincidence, naiveté and lucky mistakes ..." Kary B. Mullis (The Unusual Origin of the Polymerase Chain Reaction, Sci. Amer., April 1990, p. 445).
He testified for the defence (against PCR) at the trial of OJ Simpson.
He also believes that HIV does not cause AIDS.
He's the head of the CLBE scientific advisory board.
With the withdrawl of Vioxx and other COX-2 inhibitors, IMHO, we have seen the first of a series of failures of so-called "selective" drugs. Coupled with drug failures for other reasons (patient compliance, resistance, etc.) stem cell therapies will undoutedly play a major role in the future of medicine perhaps replacing these front-line drug treatments; however, as has been indicated, edumacation is the key...err, education and effective stem cell treatments. CLBE is money well spent but the road will be rocky (i.e., a day/swing-traders dream).
posted
The chart should not be the reason to buy this stock but it sure does looking nice: )
- The stock just crossed 50 day moving average.
-The MACD is forming an outstanding positive divergence. (A common trait in breakout stocks)
-The MACD is also getting ready to make a bullish centerline crossover.
-RSI is rising and pointing north
With these indicators and more forming, plus promising earnings being forecasted, I don't see how this is not a strong buy. JUST FACTS people. CalbaTech is compelled to have an enduring run. JMHO. Do some research. The pps is a steal under a dime.
Posts: 79 | From: California | Registered: Sep 2005
| IP: Logged |
CalbaTech's Subsidiary, LifeStem, Inc. Files Provisional Patent Application for Stem Cell Microbank and to Trademark 'Stem Cell Microbank' 11/1/2005
IRVINE, Calif., Nov 01, 2005 /PRNewswire-FirstCall via COMTEX/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, announced today that its wholly owned subsidiary, LifeStem, Inc., filed for US Trademark protection for the name of its stem cell collection service, Stem Cell Microbank, and filed a provisional patent application on the process of the Stem Cell Microbank for its process of stem cell banking. LifeStem believes that it will be the first company to focus on the micro-collection and banking of two different types of stem cells from one client.
"LifeStem's approach is based on the model that it may not be necessary to harvest a regenerative therapeutic amount of stem cells at the time of collection," said CalbaTech CEO James DeOlden. "Our collection service is unique in that stem cells will be collected in non-invasive, micro-quantities and cryo-preserved for cellular expansion at the time of use."
LifeStem, in addition to being the first company to focus on the micro-collection of stem cells, will also be the first company to offer a collection service that collects and stores two different types of stem cells for autologous use. "We believe that it is in the client's best interest to store stem cells from two tissue sources," added LifeStem President Dan Fulkerson. "By preserving two different types of stem cells on a pre-disease basis and making the cells available to the client, the client is afforded two distinct and different stem cell lineages to better suit their particular situation. The benefit to the client is that LifeStem's Microbank storage service allows the client to select the best cell source to be expanded based on the future need."
About CalbaTech
CalbaTech, Inc. (OTC Bulletin Board: CLBE) is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions.
About LifeStem
LifeStem, a wholly owned subsidiary of CalbaTech, is positioning itself to become a leading supplier of "Cellular Logistics." The Company's focus is to provide services and technologies to facilitate the efficient acquisition and delivery of adult stem cells, development of stem cell delivery devices for clinical applications and clinical applications of specific stem cell based therapies. The Company has filed a patent application for an endoscopic stem cell delivery device and plans to launch its Stem Cell Microbank in the first quarter of 2006.
Contact: Paul Knopick E&E Communications (949) 707-5365 pknopick*eandecommunications.com
Note: Certain statements in this news release may contain "forward looking" information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, may include forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will be accurate and actual results and future events could differ materially from those anticipated in such statements.
SOURCE CalbaTech, Inc.
Paul Knopick of E&E Communications, +1-949-707-5365, pknopick*eandecommunications.com, for CalbaTech, Inc. http://www.prnewswire.com
Copyright (C) 2005 PR Newswire. All rights reserved.
-------------------- Pennies...Get in, Get out, Get a profit! Posts: 352 | From: Killeen, Texas | Registered: Nov 2004
| IP: Logged |
posted
Wow, collecting two different types of stem cells while your healthy, storing them for future autologous use, should you become ill, and being able to have a choice of which of the two to expand that will be best suited for your particular future need.
This sure beats freezing your body until science can figure out to fix you.
-------------------- Pennies...Get in, Get out, Get a profit! Posts: 352 | From: Killeen, Texas | Registered: Nov 2004
| IP: Logged |
CalbaTech's Subsidiary, LifeStem, Inc. Files Provisional Patent Application for Stem Cell Microbank and to Trademark 'Stem Cell Microbank'
IRVINE, Calif., Nov. 1 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions, announced today that its wholly owned subsidiary, LifeStem, Inc., filed for US Trademark protection for the name of its stem cell collection service, Stem Cell Microbank, and filed a provisional patent application on the process of the Stem Cell Microbank for its process of stem cell banking. LifeStem believes that it will be the first company to focus on the micro-collection and banking of two different types of stem cells from one client.
"LifeStem's approach is based on the model that it may not be necessary to harvest a regenerative therapeutic amount of stem cells at the time of collection," said CalbaTech CEO James DeOlden. "Our collection service is unique in that stem cells will be collected in non-invasive, micro-quantities and cryo-preserved for cellular expansion at the time of use."
LifeStem, in addition to being the first company to focus on the micro-collection of stem cells, will also be the first company to offer a collection service that collects and stores two different types of stem cells for autologous use. "We believe that it is in the client's best interest to store stem cells from two tissue sources," added LifeStem President Dan Fulkerson. "By preserving two different types of stem cells on a pre-disease basis and making the cells available to the client, the client is afforded two distinct and different stem cell lineages to better suit their particular situation. The benefit to the client is that LifeStem's Microbank storage service allows the client to select the best cell source to be expanded based on the future need."
posted
smart money will be buying on this news,anyone can see the upcoming sequence of events that should continue to increase the value of this company. The DT's and flippers will probably scalp it for tenths of a cent but I am sure someone will be standing by ready to accumulate their shares.This is a mid to long play and should make many here wealthy if they play it right.Anyone who sells on this news is foolish
posted
should be a nice open,this patent application should be approved rather quickly since it does not involve any major trial like most drug patents.
posted
This patent will surely protect CLBE for this first time technique where as other stem cell companies will probably have to purchase a license agreement to use this technique.
CalbaTech-CLBE--this PR is just one of 3 expected concerning patents.This is a buy and hold for massive gains.For those of you who bought BIPH under a dime (thanks makingbiggdough)then you know what I mean.CLBE will be trading at or over a dollar within 6 months imo.Other stem cell companies will have to purchase Calbatechs license agreement to use this new method.
posted
its just a dip for consolidation no biggie,the lack of sellers will force them to move it.I had a 10k buy sit on .055 for a while before it took.
posted
I hope the west coast interest builds,I don't see any major resistance until .08,the high .05's is slight and very little buying pressure would break in imo.I think most simply don't realize what an opportunity this is.
posted
"plans to launch its Stem Cell Microbank in the first quarter of 2006"
" it will be the first company to focus on the micro-collection and banking of two different types of stem cells from one client"
"Our collection service is unique in that stem cells will be collected in non-invasive, micro-quantities and cryo-preserved for cellular expansion at the time of use."
filed for US Trademark protection and filed a provisional patent application on the process
posted
all I can say is be in a good stem cell stock long before the first quarter of next year.
WASHINGTON (MarketWatch) - The Senate won't act until early next year on legislation to loosen restrictions on federally funded research on embryonic stem cells, a top senator announced Friday.
In an announcement on the Senate floor, Sen. Arlen Specter, R-Pa., said that Senate Majority Leader Bill Frist, R-Tenn., "has committed to bringing it up as one of the first items next year," the Associated Press reported.
The deal eliminates a potential roadblock for a key spending bill. Specter had previously threatened to attach the legislation to the appropriations bill funding the departments of Labor and Health and Human Services - a move that was expected to delay action on the underlying legislation.
The agreement also releases Frist from a pledge to bring the stem-cell legislation to the floor this year. In July, Frist broke with President Bush and conservative Republicans by calling for an increase in federal funding.
The administration has placed strict limits on the use of federal money to fund research involving embryonic stem cells. (they will all focus on auldt stem cells imo) The White House has said Bush would likely veto legislation that loosens those limits.
Frist's endorsement puts him at odds with anti-abortion advocates within his own party, who contend that embryonic stem-cell research destroys potential human life.
Advocates of expanded funding contend that the administration's restrictions have slowed the development of treatments for a range of diseases, including Alzheimer's disease, Parkinson's disease and diabetes.
The House has already passed similar legislation and backers believe they have the votes needed to achieve passage in the Senate.
With the rate of blood diseases such as leukaemia or thalassemia increasing among the Thai population, Thai Life Insurance is now offering coverage for stem cell therapy treatments.
According to Preedee Kwan-ngam, an executive vice-president, the new plan is the first of its kind in the world, covering medical expenses for stem cell transplants.
Stem cells are cells that have the potential to develop into many different cell types in the body.
The ethics of using stem cells for research have been hotly debated as most are found at the embryonic stage. To avoid controversy, some scientists have turned to studying adult stem cells derived from blood and bones.
In Thailand, the best known case of the benefits of stem cell technology is that of Dokrak Pethprasert, a 47-year-old woman,who had a limbal stem cell transplant after going blind following treatment at a hospital.
According to Mr Preedee, the new stem cell treatment will be available as an added rider to existing health insurance policies under the Health Insurance Plus Plan.
The coverage will not include cosmetic surgery and physical rehabilitation.
Due to be introduced on Dec 1, the coverage will be available under seven plans with the amounts insured ranging from 300,000 to one million baht.
The annual premium for 300,000 baht in coverage, for instance, will be around 2,700 baht for men and 3,400 baht for women.The coverage is available for those aged from one month to 65 years.
posted
I will say this much, this is one of the most illiquid stocks I've ever seen. NITE on the bid at .0515, I put in a small order to see a few shares at .051, it executes a whole 444 shares (yes, a whopping $22 worth!!!!) and the bid drops from .0515 to .05 flat. Quest, I still say going back to the conversation late last week, there is no way to know the inventory by MM. If NITE can't get me more than 444 shares, then screw 'em all.
-------------------- I may be wrong, but I don't think so.... Posts: 837 | From: Madison, WI | Registered: Sep 2005
| IP: Logged |
posted
many will be waking up to stem cell knowledge soon especially since its going to be a $30 billion dollar industry in the next 5 years...thats a big jump from only $500 mill now.
don't worry...it will get in a real fluid state before the end of year!
posted
I think this is just the beginning,November is going to be a good month.
CalbaTech's Subsidiary, LifeStem, Inc. Files Provisional Patent ... PR Newswire (press release), NY - 12 hours ago IRVINE, Calif., Nov. 1 /PRNewswire-FirstCall/ --
CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company (http ... CalbaTech's Subsidiary, LifeStem, Inc. Files Provisional Patent ... PharmaLive.com (press release)
CalbaTech's Subsidiary, LifeStem, Inc. Files Provisional Patent ... Yahoo! News (press release) all 6 related »
CalbaTech Featured in Drug Discovery News Article PR Newswire (press release), NY - Oct 12, 2005 IRVINE, Calif., Oct. 12 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE), an emerging life sciences company ...
CalbaTech Advisory Member Contributes Stem Cell Intellectual ... PR Newswire (press release), NY - Oct 6, 2005 6 /PRNewswire-FirstCall/ -- CalbaTech, Inc. ... "We're pleased to have the support and contribution of Dr. Van Tassel," said CalbaTech CEO James DeOlden. ...
CalbaTech's Subsidiary, LifeStem, Inc., Anticipates Roll-Out of ... PR Newswire (press release), NY - Oct 5, 2005 IRVINE, Calif., Oct. 5 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC Bulletin Board ... stem cells. About CalbaTech CalbaTech, Inc. (OTC ...
CalbaTech's Subsidiary, KD Medical, Inc., Contracts With ... PR Newswire (press release), NY - Oct 10, 2005 IRVINE, Calif. and COLUMBIA, Md., Oct. 10 /PRNewswire-FirstCall/ -- CalbaTech, Inc. ... The contract is for two years. About CalbaTech CalbaTech, Inc. ...
CalbaTech's Subsidiary, LifeStem, Inc., Anticipates Roll-Out of ... Biotech Intelligence (press release), France - Oct 5, 2005 IRVINE, Calif., Oct. 5 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (BULLETIN BOARD: CLBE) , an ... CalbaTech, Inc. (BULLETIN BOARD: CLBE) is ...
(PRN) - Major Youth Football Tournament Will Kick Off in Qatar ... ... Bolsamania.com, Spain - 11 hours ago ... [+]. (PRN) - CalbaTech's Subsidiary, LifeStem, Inc. Files Provisional Patent Application for Stem Cell Microbank and to Trademark 'Stem Cell Microbank' ... [. ...
CalbaTech's Subsidiary, LifeStem, Inc., Anticipates Roll-Out of ... Yahoo! News (press release) - Oct 5, 2005 IRVINE, Calif., Oct. 5 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (OTC Bulletin Board: CLBE ... CalbaTech, Inc. (OTC Bulletin Board: CLBE ...
CalbaTech's Subsidiary, KD Medical, Inc., Contracts With ... Yahoo! News (press release) - Oct 10, 2005 IRVINE, Calif. and COLUMBIA, Md., Oct. 10 /PRNewswire-FirstCall/ -- CalbaTech, Inc. ... The contract is for two years. CalbaTech, Inc. ...
CalbaTech's Subsidiary, KD Medical, Inc., Contracts With ... PharmaLive.com (press release), PA - Oct 10, 2005 IRVINE, Calif. and COLUMBIA, Md., October 10, 2005 /PRNewswire-FirstCall/ -- CalbaTech, Inc. ... The contract is for two years. CalbaTech, Inc. ...
posted
mizzou7...of course I agree and BTW the short term rating just went to buy and hopefully mid and long follows today,the uptrend has been confirmed and this should be moving back into its normal trading range soon which is in the low .20's and imo will move much much higher pending at least to other announcements one of which is the announement of profitability this year.
Composite Indicator -- Signal -- -- Strength -- -- Direction -- Trend Spotter (TM) Buy Minimum Strongest
Short Term Indicators 7 Day Average Directional Indicator Buy Weak Strongest 10 - 8 Day Moving Average Hilo Channel Buy Minimum Strongest 20 Day Moving Average vs Price Buy Minimum Strongest 20 - 50 Day MACD Oscillator Buy Minimum Strongest 20 Day Bollinger Bands Hold Bullish
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Big Grin]](biggrin.gif)
